Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in Côte d'Ivoire: An Open-label Randomized Controlled Trial
Catherine M Bjerum, Allassane F Ouattara, Méité Aboulaye, Olivier Kouadio, Vanga K Marius, Britt J Andersen, Gary J Weil, Benjamin G Koudou, Christopher L King, Catherine M Bjerum, Allassane F Ouattara, Méité Aboulaye, Olivier Kouadio, Vanga K Marius, Britt J Andersen, Gary J Weil, Benjamin G Koudou, Christopher L King
Abstract
Background: Improved drug regimens are needed to accelerate elimination of lymphatic filariasis in Africa. This study determined whether a single co-administered dose of ivermectin plus diethylcarbamazine plus albendazole [IDA] is noninferior to standard 3 annual doses of ivermectin plus albendazole (IA) used in many LF-endemic areas of Africa.
Methods: Treatment-naive adults with Wuchereria bancrofti microfilaremia in Côte d'Ivoire were randomized to receive a single dose of IDA (n = 43) or 3 annual doses of IA (n = 52) in an open-label, single-blinded trial. The primary endpoint was the proportion of participants who were microfilaria (Mf) negative at 36 months. Secondary endpoints were Mf clearance at 6, 12, and 24 months; inactivation of adult worm nests; and safety.
Results: At 36 months posttreatment with IDA, 18/33 (55%; 95% CI, 38-72%) cleared Mf versus 33/42 (79%; 67-91%) with IA (P = .045). At 6 and 12 months IDA was superior to IA in clearing Mf (89% [77-99%] and 71% [56-85%]), respectively, versus 34% (20-48%) and 26% (14-42%) (P < .001). IDA was equivalent to IA at 24 months (61% [45-77%] vs 54% [38-72%]; P = .53). IDA was superior to IA for inactivating adult worms at all time points. Both treatments were well tolerated, and there were no serious adverse events.
Conclusions: A single dose of IDA was superior to 2 doses of IA in reducing the overall Mf burden by 24 months. Reinfection may have contributed to the lack of sustained clearance of Mf with IDA.
Clinical trials registration: NCT02974049.
Keywords: albendazole; diethylcarbamazine; efficacy; ivermectin; lymphatic filariasis.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Figures
References
- Ottesen EA, Hooper PJ, Bradley M, Biswas G. The global programme to eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop Dis 2008; 2:e317.
- Michael E, Malecela-Lazaro MN, Kazura JW. Epidemiological modelling for monitoring and evaluation of lymphatic filariasis control. Adv Parasitol 2007; 65:191–237.
- King CL, Suamani J, Sanuku N, et al. A trial of a triple-drug treatment for lymphatic filariasis. N Engl J Med 2018; 379:1801–10.
- Thomsen EK, Sanuku N, Baea M, et al. Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis. Clin Infect Dis 2016; 62:334–41.
- Weil GJ, Bogus J, Christian M, et al. ; DOLF IDA Safety Study Group The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: a multicenter, open-label, cluster-randomized study. PLoS Med 2019; 16:e1002839.
- World Health Organization. Guideline: alternative mass drug administration regimens to eliminate lymphatic filariasis. Contract No.: WHO/HTM/NTD/PCT/2017.0. Geneva, Switzerland: World Health Organization, 2017.
- Chesnais CB, Vlaminck J, Kunyu-Shako B, et al. Measurement of circulating filarial antigen levels in human blood with a point-of-care test strip and a portable spectrodensitometer. Am J Trop Med Hyg 2016; 94:1324–9.
- Chesnais CB, Missamou F, Pion SD, et al. Semi-quantitative scoring of an immunochromatographic test for circulating filarial antigen. Am J Trop Med Hyg 2013; 89:916–8.
- Moulia-Pelat JP, Glaziou P, Chanteau S, et al. Periodicity of Wuchereria bancrofti var. Pacifica filariasis in French Polynesia. Trop Med Parasitol 1993; 44:83–5.
- Weil GJ, Curtis KC, Fakoli L, et al. Laboratory and field evaluation of a new rapid test for detecting Wuchereria bancrofti antigen in human blood. Am J Trop Med Hyg 2013; 89:11–5.
- Ismail MM, Weil GJ, Jayasinghe KS, et al. Prolonged clearance of microfilaraemia in patients with bancroftian filariasis after multiple high doses of ivermectin or diethylcarbamazine. Trans R Soc Trop Med Hyg 1996; 90:684–8.
- Dreyer G, Addiss D, Noroes J, Amaral F, Rocha A, Coutinho A. Ultrasonographic assessment of the adulticidal efficacy of repeat high-dose ivermectin in bancroftian filariasis. Trop Med Int Health 1996; 1:427–32.
- Dunyo SK, Nkrumah FK, Simonsen PE. Single-dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Trans R Soc Trop Med Hyg 2000; 94:437–43.
- Dunyo SK, Nkrumah FK, Simonsen PE. A randomized double-blind placebo-controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Trans R Soc Trop Med Hyg 2000; 94:205–11.
- Ismail MM, Jayakody RL, Weil GJ, et al. Long-term efficacy of single-dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. Trans R Soc Trop Med Hyg 2001; 95:332–5.
- Ismail MM, Jayakody RL, Weil GJ, et al. Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. Trans R Soc Trop Med Hyg 1998; 92:94–7.
- Simonsen PE, Magesa SM, Dunyo SK, Malecela-Lazaro MN, Michael E. The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Trans R Soc Trop Med Hyg 2004; 98:462–72.
- Dembele B, Coulibaly YI, Dolo H, et al. Use of high-dose, twice-yearly albendazole and ivermectin to suppress Wuchereria bancrofti microfilarial levels. Clin Infect Dis 2010; 51:1229–35.
- Pion SDS, Chesnais CB, Weil GJ, Fischer PU, Missamou F, Boussinesq M. Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo. Lancet Infect Dis 2017; 17:763–9.
- Norões J, Dreyer G, Santos A, Mendes VG, Medeiros Z, Addiss D. Assessment of the efficacy of diethylcarbamazine on adult Wuchereria bancrofti in vivo. Trans R Soc Trop Med Hyg 1997; 91:78–81.
- Rizzo JA, Belo C, Lins R, Dreyer G. Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year-long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine-albendazole. Ann Trop Med Parasitol 2007; 101:423–33.
- Dreyer G, Addiss D, Norões J. Does longevity of adult Wuchereria bancrofti increase with decreasing intensity of parasite transmission? Insights from clinical observations. Trans R Soc Trop Med Hyg 2005; 99:883–92.
- Edi C, Bjerum CM, Ouattara AF, et al. Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d’Ivoire. PLoS Negl Trop Dis 2019; 13:e0007325.
- Stolk WA, Prada JM, Smith ME, et al. Are alternative strategies required to accelerate the global elimination of lymphatic filariasis? Insights from mathematical models. Clin Infect Dis 2018; 66:260–6.
- Irvine MA, Stolk WA, Smith ME, et al. Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study. Lancet Infect Dis 2017; 17:451–8.
Source: PubMed